John Zalcberg

Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.

Jean-Yves Blay, César Serrano, Michael C Heinrich, John Zalcberg, Sebastian Bauer, Hans Gelderblom, Patrick Schöffski, Robin L Jones, Steven Attia, Gina D'Amato, Ping Chi, Peter Reichardt, Julie Meade, Kelvin Shi, Rodrigo Ruiz-Soto, Suzanne George, Margaret von Mehren

Journal article  |  2020  |  The Lancet Oncology

BACKGROUND: Resistance to approved inhibitors of KIT proto-oncogene, receptor tyrosine kinase (KIT), and platelet-derived growth f..

NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121).

Mairéad Geraldine McNamara, Lipika Goyal, Mark Doherty, Christoph Springfeld, David Cosgrove, Katrin Marie Sjoquist, Joon Oh Park, Helena Verdaguer, Chiara Braconi, Paul J Ross, Aimery De Gramont, John Raymond Zalcberg, Daniel H Palmer, Juan W Valle, Jennifer J Knox

Journal article  |  2020  |  Future Oncology

Gemcitabine/cisplatin is standard of care for first-line treatment of patients with advanced biliary tract cancer (aBTC); new trea..

Real-world treatment patterns, healthcare resource use and clinical outcomes of patients receiving second line therapy for advanced or metastatic gastric cancer.

David Gómez-Ulloa, Mayur Amonkar, Smita Kothari, Winson Y Cheung, Ian Chau, John R Zalcberg, Núria Lara Suriñach, Alfredo Falcone

Journal article  |  2020  |  BMC Gastroenterology

BACKGROUND: Second-line (2 L) chemotherapies for advanced or metastatic gastric cancer have shown improved survival but there is n..

FDG-PET Follow-up of Non-Small Cell Lung Cancer: Not Dead Yet.

Rob G Stirling, John Zalcberg

Journal article  |  2020  |  The Annals of Thoracic Surgery

Comment on: 'Hospital lung surgery volume and patient outcomes'.

Rob Stirling, Michael Stenger, John Zalcberg

Journal article  |  2020  |  Lung Cancer

Developing an Australian multi-module clinical quality registry for gynaecological cancers: a protocol paper.

Natalie Heriot, Alison Brand, Paul Cohen, Sue Hegarty, Simon Hyde, Yee Leung, John R Zalcberg, Robert Rome

Journal article  |  2020  |  BMJ Open

INTRODUCTION: Gynaecological cancers collectively account for almost 10% of cancer diagnoses made in Australian women. The extent ..

Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trial.

AP Barbour, ET Walpole, GT Mai, EH Barnes, DI Watson, SP Ackland, JM Martin, M Burge, R Finch, CS Karapetis, J Shannon, LM Nott, S Varma, G Marx, GL Falk, V Gebski, M Oostendorp, K Wilson, J Thomas, G Lampe, et al.

Journal article  |  2020  |  Annals of Oncology

BACKGROUND: Patients with oesophageal/gastro-oesophageal junction adenocarcinoma (EAC) not showing early metabolic response (EMR) ..

Patient-reported outcome measures (PROMs) in pancreatic cancer: a systematic review

Ashika D Maharaj, Stella Samoborec, Sue M Evans, John Zalcberg, Rachel E Neale, David Goldstein, Neil Merrett, Kate White, Daniel Croagh, Charles HC Pilgrim, Peter Evans, Brett Knowles, Trevor Leong, Jennifer Philip, Marty Smith, Liane Ioannou

Journal article  |  2020  |  HPB

BACKGROUND: The aim of this systematic review is to examine patient-reported outcome measures (PROMs), their attributes and applic..

CD8 tumor-infiltrating lymphocytes within the primary tumor of patients with synchronous de novo metastatic colorectal carcinoma do not track with survival

R Millen, S Hendry, V Narasimhan, R Abbott, M Croxford, P Gibbs, J Tie, HL Wong, I Jones, S Kosmider, D Byrne, J Zalcberg, S Fox, J Desai, K Visvanathan, RG Ramsay, B Tran

Journal article  |  2020  |  Clinical & Translational Immunology

Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib.

John Nemunaitis, Sebastian Bauer, Jean-Yves Blay, Khalil Choucair, Hans Gelderblom, Suzanne George, Patrick Schöffski, Margaret von Mehren, John Zalcberg, Haroun Achour, Rodrigo Ruiz-Soto, Michael C Heinrich

Journal article  |  2020  |  Future Oncology

Ripretinib (DCC-2618) is a novel, type II tyrosine switch control inhibitor designed to broadly inhibit activating and drug-resist..

Implementation of the Australasian Teletrial Model: Lessons from practice

Sabe Sabesan, John Zalcberg, Craig Underhill, Rob Zielinski, Kate Burbury, Zia Ansari, Natalie Rainey, Ian Collins, Richard Osbourne, Jasotha Sanmugarajah, Anthony Joshua, Florian Honeyball, Melanie Poxton, Chantal Gebbie, Sue Jenkins Marsh, Roberta Lusa, Tyron Johnson, Amanda Garbutt, Maree Bransdon, Sue Richmond, et al.

Journal article  |  2019  |  Asia-Pacific Journal of Clinical Oncology

The Australasian tele-trial model - Access to clinical trials closer to home using tele-health

Sabe Sabesan, Andrew Bowskill, Gardiner Vicki, Chantal Gebbie, Larissa Karpish, Peter Komocki, Marie Malica, Clare Scott, Richard Vines, John Zalcberg

Conference Proceedings  |  2019  |  ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY

Patient Reported Outcome Measures (PROMs) in pancreatic cancer: a systematic review

Ashika Maharaj, Stella Samoborec, Sue M Evans, John Zalcberg, Rachel E Neale, David Goldstein, Neil Merrett, Kate White, Daniel Croagh, Charles HC Pilgrim, Peter Evans, Brett PF Knowles, Trevor Leong, Jennifer Philip, Marty Smith, Liane Ioannou

Conference Proceedings  |  2019  |  QUALITY OF LIFE RESEARCH

Challenges of international oncology trial collaboration-a call to action.

Monica Tang, Heikki Joensuu, Robert J Simes, Timothy J Price, Sonia Yip, Wendy Hague, Katrin M Sjoquist, John Zalcberg

Journal article  |  2019  |  British Journal of Cancer

International collaboration in oncology trials has the potential to enhance clinical trial activity by expediting the recruitment ..

Randomised Phase 3 Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC) - INTEGRATE II

Yu Jo Chua, Nick Pavlakis, Katrin M Sjoquist, Andrew J Martin, Eric Tsobanis, Sonia Yip, Yung-Jue Bang, Thierry Alcindor, Christopher J O'callaghan, Tanios S Bekaii-Saab, Axel Grothey, Li-Tzong Chen, John Simes, John R Zalcberg, David Goldstein, Yoshito Komatsu, Nozomu Machida, Taito Esaki, Hiroki Hara, Kohei Shitara

Conference Proceedings  |  2019  |  Annals of Oncology

The Upper Gastrointestinal Cancer Registry (UGICR): a clinical quality registry to monitor and improve care in upper gastrointestinal cancers

Ashika D Maharaj, Jennifer F Holland, Ri O Scarborough, Sue M Evans, Liane J Ioannou, Wendy Brown, Daniel G Croagh, Charles HC Pilgrim, James G Kench, Lara R Lipton, Trevor Leong, John J McNeil, Mehrdad Nikfarjam, Ahmad Aly, Paul R Burton, Paul A Cashin, Julie Chu, Cuong P Duong, Peter Evans, David Goldstein, et al.

Journal article  |  2019  |  BMJ Open

PURPOSE: The Upper Gastrointestinal Cancer Registry (UGICR) was developed to monitor and improve the quality of care provided to p..

Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer

Tomasz Burzykowski, Elisabeth Coart, Everardo D Saad, Qian Shi, Dirkje W Sommeijer, Carsten Bokemeyer, Eduardo Diaz-Rubio, Jean-Yves Douillard, Alfredo Falcone, Charles S Fuchs, Richard M Goldberg, J Randolph Hecht, Paulo M Hoff, Herbert Hurwitz, Fairooz F Kabbinavar, Miriam Koopman, Timothy S Maughan, Cornelis JA Punt, Leonard Saltz, Hans-Joachim Schmoll, et al.

Journal article  |  2019  |  JAMA Network Open

Importance: Tumor measurements can be used to estimate time to nadir and depth of nadir as potential surrogates for overall surviv..

Peeling the Onion of Health Care Disparity in Lung Cancer.

Rob Stirling, John Zalcberg

Journal article  |  2019  |  Journal of Thoracic Oncology

Towards a strategy for clinical quality registries in Australia.

Susannah Ahern, Sue Evans, Ingrid Hopper, John Zalcberg

Journal article  |  2019  |  Australian Health Review

The healthcare value of Australian clinical quality registries (CQRs) has recently been highlighted by the Australian Commission o..

Phase II trial PD-L1/PD-1 blockade avelumab with chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer: The Ave-Rec trial.

Michael Michael, Rachel Wong, Sanjeev Singh Gill, David Goldstein, Sam Ngan, Alexander Graham Heriot, Emma Link, Maria Farrell, Paul J Neeson, Robert George Ramsay, Kasmira Wilson, Catherine Mitchell, Jeanne Tie, Nick Pavlakis, John Raymond Zalcberg, Eva Segelov

Conference Proceedings  |  2019  |  Journal of Clinical Oncology

The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma.

Manfred P Lutz, John R Zalcberg, Michel Ducreux, Antoine Adenis, William Allum, Daniela Aust, Fatima Carneiro, Heike I Grabsch, Pierre Laurent-Puig, Florian Lordick, Markus Möhler, Stefan Mönig, Radka Obermannova, Guillaume Piessen, Angela Riddell, Christoph Röcken, Franco Roviello, Paul Magnus Schneider, Stefan Seewald, Elizabeth Smyth, et al.

Journal article  |  2019  |  European Journal of Cancer

Multimodal primary treatment of localised adenocarcinoma of the stomach, the oesophagus and the oesophagogastric junction (AEG) wa..

Seven electrocardiographs for seven clinical research studies.

John R Zalcberg

Journal article  |  2019  |  BMJ

Monitoring quality of care for patients with pancreatic cancer: a modified Delphi consensus

Ashika D Maharaj, Liane Ioannou, Daniel Croagh, John Zalcberg, Rachel E Neale, David Goldstein, Neil Merrett, James G Kench, Kate White, Charles HC Pilgrim, Lorraine Chantrill, Peter Cosman, Andrew Kneebone, Lara Lipton, Mehrdad Nikfarjam, Jennifer Philip, Charbel Sandroussi, Peter Tagkalidis, Richard Chye, Koroush S Haghighi, et al.

Journal article  |  2019  |  HPB

Expanded RAS and BRAF V600 testing as predictive biomarkers for single agent cetuximab in the randomized phase III CO.17 trial.

Jonathan M Loree, Anthony Dowers, Dongsheng Tu, Christopher J O'Callaghan, Dan Edelstein, Hannah Quinn, Derek J Jonker, Chris Karapetis, Timothy Jay Price, John Raymond Zalcberg, Malcolm J Moore, Paul Michael Waring, Hagen F Kennecke, Stanley R Hamilton, Scott Kopetz

Conference Proceedings  |  2019  |  Journal of Clinical Oncology

Real-world treatment patterns and clinical outcomes in patients receiving second-line (2L) treatment for advanced or metastatic gastric cancer (GC).

Mayur Amonkar, David Gomez-Ulloa, Smita Kothari, Winson Y Cheung, Ian Chau, John Raymond Zalcberg, Nuria Lara, Alfredo Falcone

Conference Proceedings  |  2019  |  Journal of Clinical Oncology

Development of a binational thyroid cancer clinical quality registry: a protocol paper.

Liane J Ioannou, Jonathan Serpell, Joanne Dean, Cino Bendinelli, Jenny Gough, Dean Lisewski, Julie A Miller, Win Meyer-Rochow, Stan Sidhu, Duncan Topliss, David Walters, John Zalcberg, Susannah Ahern

Journal article  |  2019  |  BMJ Open

INTRODUCTION: The occurrence of thyroid cancer is increasing throughout the developed world and since the 1990s has become the fas..

Clearing the air: towards agreement about access to high cost cancer medicines.

W Lipworth, I Kerridge, N Ghinea, J Zalcberg

Journal article  |  2019  |  Annals of Oncology

What matters most to patients following percutaneous coronary interventions? A new patient-reported outcome measure developed using Rasch analysis.

Sze-Ee Soh, Anna L Barker, Darshini R Ayton, Susannah Ahern, Renata Morello, Jeffrey Lefkovits, Angela L Brennan, Susan Evans, John R Zalcberg, Christopher M Reid, John J McNeil

Journal article  |  2019  |  PLOS ONE

INTRODUCTION: Measuring patient reported outcomes can improve the quality and effectiveness of healthcare interventions. The aim o..

Short-term outcome of emergency colorectal cancer surgery: results from Bi-National Colorectal Cancer Audit

Chun Hin Angus Lee, Joseph Cherng Huei Kong, Alexander G Heriot, Satish Warrier, John Zalcberg, Paul Sitzler

Journal article  |  2019  |  International Journal of Colorectal Disease

The value of participating in clinical trials: the whole is greater than the sum of its parts

John R Zalcberg, Michael Friedlander

Journal article  |  2018  |  Medical Journal of Australia

Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM (TM) system in a quaternary oncology centre

Michael Moloney, David Faulkner, Emma Link, Danny Rischin, Ben Solomon, Annette M Lim, John R Zalcberg, Michael Jefford, Michael Michael

Journal article  |  2018  |  Cancer Chemotherapy and Pharmacology

Symptoms and feelings valued by patients after a percutaneous coronary intervention: a discrete-choice experiment to inform development of a new patient-reported outcome

Anna L Barker, Geeske Peeters, Renata T Morello, Richard Norman, Darshini Ayton, Jeffrey Lefkovits, Angela Brennan, Sue M Evans, John Zalcberg, Christopher Reid, Susannah Ahern, Sze-Ee Soh, Johannes Stoelwinder, John J McNeil

Journal article  |  2018  |  BMJ Open

Developing a truly patient-derived outcome measure for cardiac procedures

Darshini Ayton, Sze-Ee Soh, Anna Barker, Susannah Ahern, Renata Morello, Jeffrey Lefkovits, Angela Brennan, Sue Evans, John Zalcberg, Christopher Reid, Johannes Stoelwinder, John McNeil

Conference Proceedings  |  2018  |  QUALITY OF LIFE RESEARCH

PD-1 blockade in renal transplant patients with poor prognosis cancer and minimizing risk of organ rejection using comprehensive immune monitoring and screening techniques: A safety study

R Carroll, JR Zalcberg, H Tang

Journal article  |  2018  |  Annals of Oncology

Progression-free survival and recurrence results for AGITG DOCTOR: Pre-op cisplatin, 5FU & DOCetaxel /-radiotherapy after poor early response to cisplatin & 5FU for resectable oesophageal adenocarcinoma

AP Barbour, ET Walpole, GT Mai, L Barnes, DI Watson, SP Ackland, V Wills, J Martin, M Burge, CS Karapetis, J Shannon, LM Nott, V Gebski, M Oostendorp, K Wilson, J Thomas, G Lampe, JR Zalcberg, J Simes, M Smithers

Journal article  |  2018  |  Annals of Oncology

Short-Term Outcomes of Emergency Colorectal Cancer Surgery: Results from Bi-National Colorectal Cancer Audit (Australia and New Zealand)

Chun HA Lee, Joseph CH Kong, Alexander G Heriot, Satish Warrier, John R Zalcberg, Paul Sitzler

Conference Proceedings  |  2018  |  Journal of the American College of Surgeons

Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group.

Kaitlyn KH Goey, Halfdan Sørbye, Bengt Glimelius, Richard A Adams, Thierry André, Dirk Arnold, Jordan D Berlin, György Bodoky, Aimery de Gramont, Eduardo Díaz-Rubio, Cathy Eng, Alfredo Falcone, Axel Grothey, Volker Heinemann, Howard S Hochster, Richard S Kaplan, Scott Kopetz, Roberto Labianca, Christopher H Lieu, Neal J Meropol, et al.

Journal article  |  2018  |  European Journal of Cancer

BACKGROUND: Patient characteristics and stratification factors are key features influencing trial outcomes. However, there is subs..

Biosimilars are coming: ready or not.

John Zalcberg

Journal article  |  2018  |  Internal Medicine Journal

Biosimilars have had a sizeable impact on the availability and use of biologic medicines in Australia, particularly those prescrib..

Potential solutions to improve the governance of multicentre health services research.

Sue M Evans, John R Zalcberg, Ri Scarborough

Journal article  |  2018  |  Medical Journal of Australia

Rationale, Opportunities, and Reality of Biosimilar Medications

John R Zalcberg

Journal article  |  2018  |  New England Journal of Medicine

PETACC-6: Preop chemoradiation and postop chemotherapy (capecitabine /- oxaliplatin) in locally advanced rectal cancer: Overall survival after long term follow-up.

H Schmoll, K Haustermans, T Price, B Nordlinger, R Hofheinz, J Daisne, J Janssens, B Brenner, P Schmidt, H Reinel, S Hollerbach, K Caca, F Fauth, C Hannig, J Zalcberg, N Tebbutt, M Mauer, S Marreaud, M Lutz, E Van Cutsem

Journal article  |  2018  |  Annals of Oncology

Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project

Katrin M Sjoquist, Lindsay A Renfro, R John Simes, Niall C Tebbutt, Stephen Clarke, Matthew T Seymour, Richard Adams, Timothy S Maughan, Leonard Saltz, Richard M Goldberg, Hans-Joachim Schmoll, Eric Van Cutsem, Jean-Yves Douillard, Paulo M Hoff, Joel Randolph Hecht, Christophe Tournigand, Cornelis JA Punt, Miriam Koopman, Herbert Hurwitz, Volker Heinemann, et al.

Journal article  |  2018  |  JNCI: Journal of the National Cancer Institute

Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial

Derek J Jonker, Louise Nott, Takayuki Yoshino, Sharlene Gill, Jeremy Shapiro, Atsushi Ohtsu, John Zalcberg, Michael M Vickers, Alice C Wei, Yuan Gao, Niall C Tebbutt, Ben Markman, Timothy Price, Taito Esaki, Sheryl Koski, Matthew Hitron, Wei Li, Youzhi Li, Nadine M Magoski, Chiang J Li, et al.

Journal article  |  2018  |  The Lancet Gastroenterology & Hepatology

Exploring patient-reported outcomes following percutaneous coronary intervention: A qualitative study.

Darshini R Ayton, Anna L Barker, Geeske MEE Peeters, Danielle E Berkovic, Jeffrey Lefkovits, Angela Brennan, Sue Evans, John Zalcberg, Christopher Reid, Johannes Just Stoelwinder, John McNeil

Journal article  |  2018  |  Health Expectations

BACKGROUND: Percutaneous coronary intervention (PCI) is a common cardiac procedure used to treat obstructive coronary artery disea..

Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW.

Kei Muro, Jae Yong Cho, Gyorgy Bodoky, Chanchal Goswami, Yee Chao, Lucas V Dos Santos, Yasuhiro Shimada, Eldar Topuzov, Eric Van Cutsem, Josep Tabernero, John Zalcberg, Ian Chau, Stefano Cascinu, Rebecca Cheng, Yanzhi Hsu, Michael Emig, Mauro Orlando, Charles Fuchs

Journal article  |  2018  |  Journal of Gastroenterology and Hepatology

BACKGROUND AND AIM: REGARD and RAINBOW were global, phase 3, randomized, double-blind trials of second-line ramucirumab for metast..

Telehealth models could be extended to conducting clinical trials-a teletrial approach.

S Sabesan, J Zalcberg

Journal article  |  2018  |  European Journal of Cancer Care

Understanding and Communicating Measures of Treatment Effect on Survival: Can We Do Better?

Everardo D Saad, John R Zalcberg, Julien Péron, Elisabeth Coart, Tomasz Burzykowski, Marc Buyse

Journal article  |  2018  |  JNCI: Journal of the National Cancer Institute

Time-to-event end points are the most frequent primary end points in phase III oncology trials, both in the adjuvant and advanced ..

Associations of incidence of common adverse events (AEs) and survival outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line chemotherapy: Findings from 9,812 pts in the ARCAD database.

Danielle Angela Ferraro, John Raymond Zalcberg, Qian Shi, Jeffrey P Meyers, Matthew T Seymour, Leonard Saltz, Tim Maughan, Richard M Goldberg, Eric Van Cutsem, Volker Heinemann, Herbert Hurwitz, Alfredo Falcone, Eduardo Diaz-Rubio, Benoist Chibaudel, Charles S Fuchs, Rainer Porschen, Carsten Bokemeyer, Aimery De Gramont, Tim Price, Richard Adams

Conference Proceedings  |  2018  |  Journal of Clinical Oncology

Telehealth

Sabe Sabesan, John Zalcberg

Journal article  |  2018  |  New England Journal of Medicine

Tools for Predicting Clinical and Patient-reported Outcomes in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: A Systematic Review of Prognostic Accuracy and Validity.

Jared M Campbell, Michael E O'Callaghan, Elspeth Raymond, Andrew D Vincent, Kerri R Beckmann, David Roder, Sue Evans, John McNeil, Jeremy Millar, John Zalcberg, Martin Borg, Kim L Moretti

Journal article  |  2017  |  Clinical Genitourinary Cancer

Androgen deprivation therapy (ADT) can result in a range of adverse symptoms that reduce patients' quality of life. Careful patien..

Tools for predicting patient-reported outcomes in prostate cancer patients undergoing radical prostatectomy: a systematic review of prognostic accuracy and validity.

ME O'Callaghan, E Raymond, J Campbell, AD Vincent, K Beckmann, D Roder, S Evans, J McNeil, J Millar, J Zalcberg, M Borg, K Moretti

Journal article  |  2017  |  Prostate Cancer and Prostatic Diseases

BACKGROUND: Radical prostatectomy is a common surgical procedure performed to treat prostate cancer. Patient-reported outcomes aft..

Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis

EK Morgen, H-J Lenz, DJ Jonker, D Tu, G Milano, F Graziano, J Zalcberg, CS Karapetis, A Dobrovic, CJ O'Callaghan, G Liu

Journal article  |  2017  |  The Pharmacogenomics Journal

Optimum Tools for Predicting Clinical Outcomes in Prostate Cancer Patients Undergoing Radical Prostatectomy: A Systematic Review of Prognostic Accuracy and Validity.

Jared M Campbell, Elspeth Raymond, Michael E O'Callaghan, Andrew D Vincent, Kerri R Beckmann, David Roder, Sue Evans, John McNeil, Jeremy Millar, John Zalcberg, Martin Borg, Kim L Moretti

Journal article  |  2017  |  Clinical Genitourinary Cancer

Prostate cancer is a heterogeneous disease whose therapies frequently have adverse effects. Informed patient counseling regarding ..

"Mind the Gap" Revisited.

John R Zalcberg, Michael Wonder

Journal article  |  2017  |  Seminars in Oncology

Do all services provided as part of a clinical trial require research ethics and governance review?

Jeremy Kenner, John R Zalcberg

Journal article  |  2017  |  Internal Medicine Journal

Appropriate ethical oversight underpins the conduct of all clinical trials in Australia. In addition, clinical trials require a su..

TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG

Trevor Leong, B Mark Smithers, Karin Haustermans, Michael Michael, Val Gebski, Danielle Miller, John Zalcberg, Alex Boussioutas, Michael Findlay, Rachel L O'Connell, Jaclyn Verghis, David Willis, Tomas Kron, Melissa Crain, William K Murray, Florian Lordick, Carol Swallow, Gail Darling, John Simes, Rebecca Wong

Journal article  |  2017  |  Annals of Surgical Oncology

3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer.

Manfred P Lutz, John R Zalcberg, Michel Ducreux, Daniela Aust, Marco J Bruno, Markus W Büchler, Jean-Robert Delpero, Beat Gloor, Rob Glynne-Jones, Werner Hartwig, Florence Huguet, Pierre Laurent-Puig, Florian Lordick, Patrick Maisonneuve, Julia Mayerle, Marc Martignoni, John Neoptolemos, Andrew D Rhim, Bruno M Schmied, Thomas Seufferlein, et al.

Conference Proceedings  |  2017  |  European Journal of Cancer

The primary treatment of pancreatic cancer was the topic of the 3rd St. Gallen Conference 2016. A multidisciplinary panel reviewed..

Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study

Brian G Czito, Dustin A Deming, Gayle S Jameson, Mary F Mulcahy, Houman Vaghefi, Matthew W Dudley, Kyle D Holen, Angela DeLuca, Rajendar K Mittapalli, Wijith Munasinghe, Lei He, John R Zalcberg, Samuel Y Ngan, Philip Komarnitsky, Michael Michael

Journal article  |  2017  |  The Lancet Gastroenterology & Hepatology

Patient-Reported Outcomes After Radiation Therapy in Men With Prostate Cancer: A Systematic Review of Prognostic Tool Accuracy and Validity.

Michael E O'Callaghan, Elspeth Raymond, Jared M Campbell, Andrew D Vincent, Kerri Beckmann, David Roder, Sue Evans, John McNeil, Jeremy Millar, John Zalcberg, Martin Borg, Kim Moretti

Journal article  |  2017  |  International Journal of Radiation Oncology*Biology*Physics

PURPOSE: To identify, through a systematic review, all validated tools used for the prediction of patient-reported outcome measure..

Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels

Paolo G Casali, John Zalcberg, Axel Le Cesne, Peter Reichardt, Jean-Yves Blay, Lars H Lindner, Ian R Judson, Patrick Schoffski, Serge Leyvraz, Antoine Italiano, Viktor Grunwald, Antonio Lopez Pousa, Dusan Kotasek, Stefan Sleijfer, Jan M Kerst, Piotr Rutkowski, Elena Fumagalli, Pancras Hogendoorn, Saskia Litiere, Sandrine Marreaud, et al.

Journal article  |  2017  |  Journal of Clinical Oncology

An International Collaborative Standardizing a Comprehensive Patient-Centered Outcomes Measurement Set for Colorectal Cancer

Jessica A Zerillo, Maartje G Schouwenburg, Annelotte CM van Bommel, Caleb Stowell, Jacob Lippa, Donna Bauer, Ann M Berger, Gilles Boland, Josep M Borras, Mary K Buss, Robert Cima, Eric Van Cutsem, Eino B van Duyn, Samuel RG Finlayson, Skye Hung-Chun Cheng, Corinna Langelotz, John Lloyd, Andrew C Lynch, Harvey J Mamon, Pamela K McAllister, et al.

Journal article  |  2017  |  JAMA Oncology

A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group.

H Bleiberg, G Decoster, A de Gramont, P Rougier, A Sobrero, A Benson, B Chibaudel, JY Douillard, C Eng, C Fuchs, M Fujii, R Labianca, AK Larsen, E Mitchell, HJ Schmoll, D Sprumont, J Zalcberg

Journal article  |  2017  |  Annals of Oncology

Background: In respect of the principle of autonomy and the right of self-determination, obtaining an informed consent of potentia..

An appraisal of analytical tools used in predicting clinical outcomes following radiation therapy treatment of men with prostate cancer: a systematic review.

Elspeth Raymond, Michael E O'Callaghan, Jared Campbell, Andrew D Vincent, Kerri Beckmann, David Roder, Sue Evans, John McNeil, Jeremy Millar, John Zalcberg, Martin Borg, Kim Moretti

Journal article  |  2017  |  Radiation Oncology

BACKGROUND: Prostate cancer can be treated with several different modalities, including radiation treatment. Various prognostic to..

Tumor-size-based endpoints as surrogates for overall survival in the ARCAD Advanced Colorectal Cancer Database.

Tomasz Burzykowski, Elisabeth Coart, Everardo D Saad, Dan Sargent, John Raymond Zalcberg, Qian Shi, Dirkje Willemien Sommeijer, Marc E Buyse

Conference Proceedings  |  2017  |  Journal of Clinical Oncology

Efficacy and safety of ramucirumab (RAM) for metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma across age subgroups in two global phase 3 trials.

Kei Muro, Jae Yong Cho, Gyorgy Bodoky, Chanchal Goswami, Yee Chao, Lucas Vieira dos Santos, Yasuhiro Shimada, Eldar Topuzov, Eric Van Cutsem, Josep Tabernero, John Raymond Zalcberg, Ian Chau, Rebecca Cheng, Yanzhi Hsu, Michael Emig, Mauro Orlando, Hansjochen Wilke, Charles S Fuchs

Conference Proceedings  |  2017  |  Journal of Clinical Oncology

Music's Relevance for People Affected by Cancer: A Meta-Ethnography and Implications for Music Therapists

Clare C O'Callaghan, Fiona McDermott, Philippa Reid, Natasha Michael, Peter Hudson, John R Zalcberg, Jane Edwards

Journal article  |  2016  |  Journal of Music Therapy

Enough is enough … a call to action to improve ethical and governance review processes in Australia.

SM Evans, JR Zalcberg

Journal article  |  2016  |  Internal Medicine Journal

Erratum: Corrigendum to “2nd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer” (European Journal of Cancer (2016) 68 (208–209) (S0959804916320780) (10.1016/j.ejca.2016.04.010))

MP Lutz, JR Zalcberg, R Glynne-Jones, T Ruers, M Ducreux, D Arnold, D Aust, G Brown, K Bujko, C Cunningham, S Evrard, G Folprecht, JP Gerard, A Habr-Gama, K Haustermans, T Holm, KF Kuhlmann, F Lordick, G Mentha, M Moehler, et al.

Journal article  |  2016  |  European Journal of Cancer

Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer: final analyses

HJ Schmoll, A Stein, RD Hofheinz, TJ Price, B Nordlinger, JF Daisne, J Janssens, B Brenner, P Schmidt, H Reinel, S Hollerbach, K Caca, F Fauth, J Zalcberg, S Marreaud, M Mauer, M Lutz, E Van Cutsem, K Haustermans

Journal article  |  2016  |  Annals of Oncology

A randomized phase III study of napabucasin [BBI608] (NAPA) vs placebo (PBO) in patients (pts) with pretreated advanced colorectal cancer (ACRC): the CCTG/AGITG CO.23 trial

DJ Jonker, L Nott, T Yoshino, S Gill, J Shapiro, A Ohtsu, J Zalcberg, MM Vickers, A Wei, Y Gao, N Tebbutt, B Markman, T Esaki, S Koski, M Hitron, NM Magoski, J Simes, C Li, D Tu, CJ O'Callaghan

Journal article  |  2016  |  Annals of Oncology

An AGITG trial –A randomised phase II study of pre-operative cisplatin, fluorouracil and DOCetaxel /-radioTherapy based on poOR early response to cisplatin and fluorouracil for resectable esophageal adenocarcinoma

A Barbour, E Walpole, GT Mai, H Chan, E Barnes, D Watson, S Ackland, V Wills, J Martin, M Burge, C Karapetis, J Shannon, L Nott, V Gebski, K Wilson, J Thomas, G Lampe, J Zalcberg, J Simes, M Smithers

Journal article  |  2016  |  Annals of Oncology

Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial

Nick Pavlakis, Katrin M Sjoquist, Andrew J Martin, Eric Tsobanis, Sonia Yip, Yoon-Koo Kang, Yung-Jue Bang, Thierry Alcindor, Christopher J O'Callaghan, Margot J Burnell, Niall C Tebbutt, Sun Young Rha, Jeeyun Lee, Jae-Yong Cho, Lara R Lipton, Mark Wong, Andrew Strickland, Jin Won Kim, John R Zalcberg, John Simes, et al.

Journal article  |  2016  |  Journal of Clinical Oncology

TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer

D Ferraro, D Goldstein, RL O'Connell, JR Zalcberg, KM Sjoquist, NC Tebbutt, P Grimison, S McLachlan, LL Lipton, P Vasey, VJ Gebski, C Aiken, M Cronk, S Ng, CS Karapetis, J Shannon

Journal article  |  2016  |  Cancer Chemotherapy and Pharmacology

Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer.

Manfred P Lutz, John R Zalcberg, Rob Glynne-Jones, Theo Ruers, Michel Ducreux, Dirk Arnold, Daniela Aust, Gina Brown, Krzysztof Bujko, Christopher Cunningham, Serge Evrard, Gunnar Folprecht, Jean-Pierre Gerard, Angelita Habr-Gama, Karin Haustermans, Torbjörn Holm, Koert F Kuhlmann, Florian Lordick, Gilles Mentha, Markus Moehler, et al.

Journal article  |  2016  |  European Journal of Cancer

Primary treatment of rectal cancer was the focus of the second St. Gallen European Organisation for Research and Treatment of Canc..

Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study

G Folprecht, C Pericay, MP Saunders, A Thomas, R Lopez Lopez, JK Roh, V Chistyakov, T Hoehler, J-S Kim, R-D Hofheinz, SP Ackland, D Swinson, M Kopp, D Udovitsa, M Hall, T Iveson, A Vogel, JR Zalcberg

Journal article  |  2016  |  Annals of Oncology

Fc-gamma Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer

Geoffrey Liu, Dongsheng Tu, Marcia Lewis, Dangxiao Cheng, Leslie A Sullivan, Zhuo Chen, Eric Morgen, John Simes, Timothy J Price, Niall C Tebbutt, Jeremy D Shapiro, G Mark Jeffery, J Daniel Mellor, Thomas Mikeska, Shakeel Virk, Lois E Shepherd, Derek J Jonker, Christopher J O'Callaghan, John R Zalcberg, Christos S Karapetis, et al.

Journal article  |  2016  |  Clinical Cancer Research

Serious adverse event reporting in investigator-initiated clinical trials

Sophie Wallace, Paul S Myles, Nikolajs Zeps, John R Zalcberg

Journal article  |  2016  |  Medical Journal of Australia

The impact on health-related quality of life in the first 12 months: A randomised comparison of preoperative short-course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04)

Sue-Anne McLachlan, Richard J Fisher, John Zalcberg, Michael Solomon, Bryan Burmeister, David Goldstein, Trevor Leong, Stephen P Ackland, Joseph McKendrick, Bev McClure, John Mackay, Samuel Y Ngan

Journal article  |  2016  |  European Journal of Cancer

Development of South Australian-Victorian Prostate Cancer Health Outcomes Research Dataset.

Rasa Ruseckaite, Kerri Beckmann, Michael O'Callaghan, David Roder, Kim Moretti, John Zalcberg, Jeremy Millar, Sue Evans

Journal article  |  2016  |  BMC Research Notes

BACKGROUND: Prostate cancer is the most commonly diagnosed and prevalent malignancy reported to Australian cancer registries, with..

Advances in Molecular Pathology and Treatment of Periampullary Cancers.

Manju D Chandrasegaram, John W Chen, Timothy J Price, John Zalcberg, Katrin Sjoquist, Neil D Merrett

Journal article  |  2016  |  Pancreas

OBJECTIVES: Periampullary cancers (PACs) include the following 4 traditional anatomic subtypes: pancreatic, ampullary, biliary, or..

Colorectal cancer

Alex Boussioutas, Stephen Fox, Iris Nagtegaal, Alexander Heriot, Jonathan Knowles, Michael Michael, Sam Ngan, Kathryn Field, John Zalcberg

Book Chapter  |  2016

This chapter covers colorectal cancer, and includes information on epidemiology, risk factors (chronic inflammation/inflammatory b..

Reply

JR Zalcberg, XF Hu

Journal article  |  2016  |  Cancer Research

Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas

Paolo G Casali, Axel Le Cesne, Andres Poveda Velasco, Dusan Kotasek, Piotr Rutkowski, Peter Hohenberger, Elena Fumagalli, Ian R Judson, Antoine Italiano, Hans Gelderblom, Antoine Adenis, Jorg T Hartmann, Florence Duffaud, David Goldstein, Javier M Broto, Alessandro Gronchi, Angelo P Dei Tos, Sandrine Marreaud, Winette TA van der Graaf, John R Zalcberg, et al.

Journal article  |  2015  |  Journal of Clinical Oncology

Oxaliplatin/5-fluorouracil-based adjuvant chemotherapy as a standard of care for colon cancer in clinical practice: Outcomes of the ACCElox registry

Young Suk Park, Jiafu Ji, John Raymond Zalcberg, Mostafa El-Serafi, Antonio Buzaid, Marwan Ghosn

Journal article  |  2015  |  Asia-Pacific Journal of Clinical Oncology

Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting.

Diether Lambrechts, Bernard Thienpont, Vincent Thuillier, Xavier Sagaert, Matthieu Moisse, Gilian Peuteman, Carles Pericay, Gunnar Folprecht, John Zalcberg, Chiara Zilocchi, Emmanuelle Margherini, Marielle Chiron, Eric Van Cutsem

Journal article  |  2015  |  British Journal of Cancer

BACKGROUND: Aflibercept (ziv-aflibercept) is an anti-angiogenic agent recently approved in combination with FOLFIRI for the treatm..

Clinical utility of ramucirumab in advanced gastric cancer

MMK Chan, KM Sjoquist, JR Zalcberg

Journal article  |  2015  |  Biologics: Targets and Therapy

Views of Australian Medical Oncologists Regarding the Use of Mismatch Repair Status to Assist Adjuvant Chemotherapy Recommendations for Patients With Early-Stage Colon Cancer

Kiley WJ Loh, Michael Michael, John R Zalcberg, Michael Jefford

Journal article  |  2015  |  Clinical Colorectal Cancer

TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG)

Trevor Leong, B Mark Smithers, Michael Michael, Val Gebski, Alex Boussioutas, Danielle Miller, John Simes, John Zalcberg, Karin Haustermans, Florian Lordick, Christoph Schuhmacher, Carol Swallow, Gail Darling, Rebecca Wong

Journal article  |  2015  |  BMC CANCER

Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17

SY Brule, DJ Jonker, CS Karapetis, CJ O'Callaghan, MJ Moore, R Wong, NC Tebbutt, Cr Underhill, D Yip, JR Zalcberg, D Tu, RA Goodwin

Journal article  |  2015  |  European Journal of Cancer

Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.

Guillem Argilés, Mark P Saunders, Fernando Rivera, Alberto Sobrero, Al Benson, Carmen Guillén Ponce, Stefano Cascinu, Eric Van Cutsem, Iain R Macpherson, Dirk Strumberg, Claus-Henning Köhne, John Zalcberg, Andrea Wagner, Vittorio Luigi Garosi, Julia Grunert, Josep Tabernero, Fortunato Ciardiello

Journal article  |  2015  |  European Journal of Cancer

BACKGROUND: The oral multikinase inhibitor regorafenib improves overall survival (OS) in patients with metastatic colorectal cance..

Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib

Chee Khoon Lee, David Goldstein, Emma Gibbs, Heikki Joensuu, John Zalcberg, Jaap Verweij, Paolo G Casali, Robert G Maki, Angela Cioffi, Grant Mcarthur, Sarah J Lord, Desmond Yip, Yada Kanjanapan, Piotr Rutkowski

Journal article  |  2015  |  European Journal of Cancer

Accepting risk in the acceleration of drug development for rare cancers

David Ashley, David Thomas, Lia Gore, Rob Carter, John R Zalcberg, Renee Otmar, Julian Savulescu

Journal article  |  2015  |  The Lancet Oncology

Gastric cancer: past progress and present challenges.

Katrin M Sjoquist, John R Zalcberg

Journal article  |  2015  |  Gastric Cancer

NEUROENDOCRINE TUMOURS - MODELS FOR RARE TUMOUR MANAGEMENT

David L Chan, David Goldstein, John R Zalcberg

Journal article  |  2015  |  Cancer Forum

An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer

Yeh Chen Lee, Michael Michael, John R Zalcberg

Journal article  |  2015  |  Expert Opinion on Investigational Drugs

Bespoke treatment: Drivers beware!

Sharon Pattison, John R Zalcberg

Journal article  |  2014  |  Asia-Pacific Journal of Clinical Oncology

Phase II trial evaluating the feasibility of interdigitating folfox with chemoradiotherapy in locally advanced and metastatic rectal cancer

M Michael, S Chander, J McKendrick, JR MacKay, M Steel, R Hicks, A Heriot, T Leong, P Cooray, M Jefford, J Zalcberg, M Bressel, B McClure, SY Ngan

Journal article  |  2014  |  British Journal of Cancer

Realising opportunities for evidence-based cancer service delivery and research: linking cancer registry and administrative data in Australia.

DM Roder, KM Fong, MP Brown, J Zalcberg, CE Wainwright

Journal article  |  2014  |  European Journal of Cancer Care

The traditional roles of Australian cancer registries have been incidence, mortality and survival surveillance although increasing..

Broken doctor-patient relationships: why won't they listen? Patient-doctor relationships may break down. We present and discuss a hypothetical case

Michael Jefford, John R Zalcberg

Journal article  |  2014  |  Medical Journal of Australia

Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy

Danielle Ferraro, John Zalcberg

Journal article  |  2014  |  Therapeutic Advances in Medical Oncology

Controversies in the management of gastrointestinal stromal tumors

Desmond Yip, John Zalcberg, Stephen Ackland, Andrew P Barbour, Jayesh Desai, Stephen Fox, Dusan Kotasek, Grant McArthur, B Mark Smithers

Journal article  |  2014  |  Asia-Pacific Journal of Clinical Oncology

The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17

Dirkje W Sommeijer, Christos S Karapetis, John R Zalcberg, Dongsheng Tu, Derek J Jonker, John Simes, Niall Tebbutt, Desmond Yip, Timothy J Price, Chris J O'Callaghan

Journal article  |  2014  |  Acta Oncologica

Preoperative Chemoradiotherapy and Postoperative Chemotherapy with Capecitabine and Oxaliplatin Vs. Capecitabine Alone in Locally Advanced Rectal Cancer: Disease Free Survival at Interim Analysis

HJ Schmoll, K Haustermans, T Price, B Nordlinger, R Hofheinz, JF Daisne, J Janssens, B Brenner, P Schmidt, H Reinel, S Hollerbach, K Caca, F Fauth, CV Hannig, J Zalcberg, N Tebbutt, M Mauer, C Messina, M Lutz, E Van Cutsem

Journal article  |  2014  |  Annals of Oncology

"A quiet still voice that just touches": music's relevance for adults living with life-threatening cancer diagnoses

Clare C O'Callaghan, Fiona McDermott, Natasha Michael, Barbara A Daveson, Peter L Hudson, John R Zalcberg

Journal article  |  2014  |  Supportive Care in Cancer

Registry of gastric cancer treatment evaluation (REGATE): I baseline disease characteristics

Yung-Jue Bang, Suayib Yalcin, Arnaud Roth, Simon Hitier, Mikhail Ter-Ovanesov, Chew-Wun Wu, John Zalcberg

Journal article  |  2014  |  Asia-Pacific Journal of Clinical Oncology

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer

DJ Jonker, CS Karapetis, C Harbison, CJ O'Callaghan, D Tu, RJ Simes, DP Malone, C Langer, N Tebbutt, TJ Price, J Shapiro, LL Siu, RPW Wong, G Bjarnason, MJ Moore, JR Zalcberg, S Khambata-Ford

Journal article  |  2014  |  British Journal of Cancer

PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer-Results from NCIC CTG/AGITG CO.17

Christos S Karapetis, Derek Jonker, Manijeh Daneshmand, Jennifer E Hanson, Christopher J O'Callaghan, Celia Marginean, John R Zalcberg, John Simes, Malcolm J Moore, Niall C Tebbutt, Timothy J Price, Jeremy D Shapiro, Nick Pavlakis, Peter Gibbs, Guy A Van Hazel, Ursula Lee, Rashida Haq, Shakeel Virk, Dongsheng Tu, Ian AJ Lorimer

Journal article  |  2014  |  Clinical Cancer Research

Quality of Life in Patients With K-RAS Wild-Type Colorectal Cancer

Jolie Ringash, Heather-Jane Au, Lillian L Siu, Jeremy D Shapiro, Derek J Jonker, John R Zalcberg, Malcolm J Moore, Andrew Strickland, Rami Kotb, Mark Jeffery, Thierry Alcindor, Siobhan Ng, Muhammad Salim, Sabe Sabesan, Jay C Easaw, Jenny Shannon, Fabyolla El-Tahche, Ian Walters, Dongsheng Tu, Christopher J O'Callaghan

Journal article  |  2014  |  Cancer

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Charles S Fuchs, Jiri Tomasek, Cho Jae Yong, Filip Dumitru, Rodolfo Passalacqua, Chanchal Goswami, Howard Safran, Lucas Vieira dos Santos, Giuseppe Aprile, David R Ferry, Bohuslav Melichar, Mustapha Tehfe, Eldar Topuzov, John Raymond Zalcberg, Ian Chau, William Campbell, Choondal Sivanandan, Joanna Pikiel, Minori Koshiji, Yanzhi Hsu, et al.

Journal article  |  2014  |  The Lancet

Adjuvant therapy for colorectal cancer

M Michael, JR Zalcberg

Journal article  |  2014  |  Cancer Forum

Registry of gastric cancer treatment evaluation (REGATE): II treatment practice

Mikhail Ter-Ovanesov, Suayib Yalcin, John Zalcberg, Simon Hitier, Yung-Jue Bang, Chew-Wun Wu, Arnaud Roth

Journal article  |  2013  |  Asia Pacific Journal of Clinical Oncology

Phase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in Patients With Metastatic, Chemotherapy-Refractory, Wild-Type K-RAS Colorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial

Lillian L Siu, Jeremy D Shapiro, Derek J Jonker, Chris S Karapetis, John R Zalcberg, John Simes, Felix Couture, Malcolm J Moore, Timothy J Price, Jehan Siddiqui, Louise M Nott, Danielle Charpentier, Winston Liauw, Michael B Sawyer, Michael Jefford, Nadine M Magoski, Andrew Haydon, Ian Walters, Jolie Ringash, Dongsheng Tu, et al.

Journal article  |  2013  |  Journal of Clinical Oncology

Clinical trials - Advancing national cancer care

KM Sjoquist, JR Zalcberg

Journal article  |  2013  |  Cancer Forum

A phase I trial of imatinib in combination with mFOLFOX6-bevacizumab in patients with advanced colorectal cancer

M Michael, J Zalcberg, P Gibbs, L Lipton, M Gouillou, M Jefford, G McArthur, M Copeman, K Lynch, NC Tebbutt

Journal article  |  2013  |  CANCER CHEMOTHERAPY AND PHARMACOLOGY

Sound Continuing Bonds with the Deceased: The Relevance of Music, Including Preloss Music Therapy, for Eight Bereaved Caregivers

Clare C O'Callaghan, Fiona McDermott, Peter Hudson, John R Zalcberg

Journal article  |  2013  |  Death Studies

A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer

James D Mellor, Michael P Brown, Helen R Irving, John R Zalcberg, Alexander Dobrovic

Journal article  |  2013  |  Journal of Hematology & Oncology

Reducing clinical trial monitoring resource allocation and costs through remote access to electronic medical records.

Shannon C Uren, Mitchell B Kirkman, Brad S Dalton, John R Zalcberg

Journal article  |  2013  |  Journal of Oncology Practice

PURPOSE: With electronic medical records (eMRs), the option now exists for clinical trial monitors to perform source data verifica..

Randomized Trial of Short-Course Radiotherapy Versus Long-Course Chemoradiation Comparing Rates of Local Recurrence in Patients With T3 Rectal Cancer: Trans-Tasman Radiation Oncology Group Trial 01.04

Samuel Y Ngan, Bryan Burmeister, Richard J Fisher, Michael Solomon, David Goldstein, David Joseph, Stephen P Ackland, David Schache, Bev McClure, Sue-Anne McLachlan, Joseph McKendrick, Trevor Leong, Cris Hartopeanu, John Zalcberg, John Mackay

Journal article  |  2012  |  Journal of Clinical Oncology

Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - Differential treatment strategies for subtypes of early gastroesophageal cancer

Manfred P Lutz, John R Zalcberg, Michel Ducreux, Jaffer A Ajani, William Allum, Daniela Aust, Yung-Jue Bang, Stefano Cascinu, Arnulf Hoelscher, Janusz Jankowski, Edwin PM Jansen, Ralf Kisslich, Florian Lordick, Christophe Mariette, Markus Moehler, Tsuneo Oyama, Arnaud Roth, Josef Rueschoff, Thomas Ruhstaller, Raquel Seruca, et al.

Journal article  |  2012  |  European Journal of Cancer

Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors

Damien Kee, John R Zalcberg

Journal article  |  2012  |  Therapeutic Advances in Medical Oncology

The Role of Biological Agents in the Resection of Colorectal Liver Metastases

B Nordlinger, R Adam, D Arnold, JR Zalcberg, T Gruenberger

Journal article  |  2012  |  Clinical Oncology

Dose optimization of tyrosine kinase inhibitors to improve outcomes in GIST

John R Zalcberg, Jayesh Desai

Journal article  |  2012  |  Asia Pacific Journal of Clinical Oncology

Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis (vol 47, pg 1826, 2011)

Stephen J Clarke, Sonia Yip, Chris Brown, Guy A van Hazel, David T Ransom, David Goldstein, G Mark Jeffrey, Niall C Tebbutt, Martin Buck, Raymond M Lowenthal, Amy Boland, Val Gebski, John Zalcberg, R John Simes

Journal article  |  2012  |  European Journal of Cancer

Comparative effectiveness research - a proposal for a new NHMRC funding stream

John R Zalcberg

Journal article  |  2012  |  Medical Journal of Australia

Neurofibromatosis type 1-associated wild-type gastrointestinal stromal tumor treated with anti-IGF-1R monoclonal antibody

FL Day, J Desai, CL Corless, MC Heinrich, J Zalcberg

Journal article  |  2011  |  Medical Oncology

Overview of controversies in oesophagogastric cancer

A Cameron, KM Sjoquist, JR Zalcberg

Journal article  |  2011  |  Cancer Forum

Delivering affordable cancer care in high-income countries

Richard Sullivan, Jeffrey Peppercorn, Karol Sikora, John Zalcberg, Neal J Meropol, Eitan Amir, David Khayat, Peter Boyle, Philippe Autier, Ian F Tannock, Tito Fojo, Jim Siderov, Steve Williamson, Silvia Camporesi, J Gordon McVie, Arnie D Purushotham, Peter Naredi, Alexander Eggermont, Murray F Brennan, Michael L Steinberg, et al.

Journal article  |  2011  |  The Lancet Oncology

What constitutes a multidisciplinary team meeting?

Linda Mileshkin, John Zalcberg

Journal article  |  2011  |  Asia-Pacific Journal of Clinical Oncology

Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis

Stephen J Clarke, Sonia Yip, Chris Brown, Guy A van Hazel, David T Ransom, David Goldstein, G Mark Jeffrey, Niall C Tebbutt, Martin Buck, Raymond M Lowenthal, Amy Boland, Val Gebski, John Zalcberg, R John Simes

Journal article  |  2011  |  European Journal of Cancer

Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis

Katrin M Sjoquist, Bryan H Burmeister, B Mark Smithers, John R Zalcberg, R John Simes, Andrew Barbour, Val Gebski

Journal article  |  2011  |  Lancet Oncology

Biological markers in patients with early-stage colon cancer: Consensus and controversies

KM Field, JR Zalcberg

Journal article  |  2011  |  Current Colorectal Cancer Reports

The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010

E Van Cutsem, M Dicato, R Geva, N Arber, Y Bang, A Benson, A Cervantes, E Diaz-Rubio, M Ducreux, R Glynne-Jones, A Grothey, D Haller, K Haustermans, D Kerr, B Nordlinger, J Marshall, BD Minsky, YK Kang, R Labianca, F Lordick, et al.

Journal article  |  2011  |  Annals of Oncology

Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer

FL Day, T Leong, S Ngan, R Thomas, M Jefford, JR Zalcberg, D Rischin, J McKendick, AD Milner, J Di Iulio, A Matera, M Michael

Journal article  |  2011  |  British Journal of Cancer

Gastrointestinal Stromal Tumors

John R Zalcberg, Desmond Yip, Christine Hemmings, Bruce Mann, Charles D Blanke

Book Chapter  |  2011

A survey of reimbursement practices of private health insurance companies for pharmaceuticals not covered under the Pharmaceutical Benefits Scheme 2008

Senthil M Lingaratnam, Sue W Kirsa, James D Mellor, John Jackson, Wallace Crellin, Michael Fitzsimons, John R Zalcberg

Journal article  |  2011  |  Australian Health Review

Music Among Family Carers of People With Life-Threatening Cancer

CC O’callaghan, P Hudson, M Fiona, JR Zalcberg

Journal article  |  2011  |  Music and Medicine

Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab

Wendy De Roock, Derek J Jonker, Federica Di Nicolantonio, Andrea Sartore-Bianchi, Dongsheng Tu, Salvatore Siena, Simona Lamba, Sabrina Arena, Milo Frattini, Hubert Piessevaux, Eric Van Cutsem, Chris J O'Callaghan, Shirin Khambata-Ford, John R Zalcberg, John Simes, Christos S Karapetis, Alberto Bardelli, Sabine Tejpar

Journal article  |  2010  |  JAMA: Journal of the American Medical Association

Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study

Niall C Tebbutt, Kate Wilson, Val J Gebski, Michelle M Cummins, Diana Zannino, Guy A van Hazel, Bridget Robinson, Adam Broad, Vinod Ganju, Stephen P Ackland, Garry Forgeson, David Cunningham, Mark P Saunders, Martin R Stockler, YuJo Chua, John R Zalcberg, R John Simes, Timothy J Price

Journal article  |  2010  |  Journal of Clinical Oncology

Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial

NC Tebbutt, MM Cummins, T Sourjina, A Strickland, G Van Hazel, V Ganju, D Gibbs, M Stockler, V Gebski, J Zalcberg

Journal article  |  2010  |  British Journal of Cancer

Antitumor Effect of Somatostatin Analogs in Neuroendocrine Tumors

Yu Jo Chua, Michael Michael, John R Zalcberg, Rod J Hicks, David Goldstein, Winston Liauw, Timothy Price

Journal article  |  2010  |  Journal of Clinical Oncology

Radiology reporting templates in oncology: A time for change

D Kee, JR Zalcberg

Journal article  |  2009  |  Journal of Medical Imaging and Radiation Oncology

To Tell or Not to Tell: The Community Wants to Know About Expensive Anticancer Drugs As a Potential Treatment Option

Linda Mileshkin, Penelope E Schofield, Michael Jefford, Emilia Agalianos, Michele Levine, Alan Herschtal, Julian Savulescu, Jacqui Ann Thomson, John R Zalcberg

Journal article  |  2009  |  Journal of Clinical Oncology

Discussing Expensive Anticancer Drugs

Michael Jefford, Linda Mileshkin, Penelope Schofield, Emilia Agalianos, Jacqui Thomson, John Zalcberg

Journal article  |  2009  |  Journal of Clinical Oncology

A phase I trial of Capecitabine plus Gemcitabine with radical radiation for locally advanced pancreatic cancer

M Michael, T Price, SY Ngan, V Ganju, AH Strickland, A Muller, K Khamly, AD Milner, J Dilulio, A Matera, JR Zalcberg, T Leong

Journal article  |  2009  |  British Journal of Cancer

Progress in targeted therapies for cancer: Overview

B Solomon, J Zalcberg

Journal article  |  2008  |  Cancer Forum

K-ras mutations and benefit from cetuximab in advanced colorectal cancer

Christos S Karapetis, Shirin Khambata-Ford, Derek J Jonker, Chris J O'Callaghan, Dongsheng Tu, Niall C Tebbutt, R John Simes, Haji Chalchal, Jeremy D Shapiro, Sonia Robitaille, Timothy J Price, Lois Shepherd, Heather-Jane Au, Christiane Langer, Malcolm J Moore, John R Zalcberg

Journal article  |  2008  |  New England Journal of Medicine

Pancreatic cancer - is the wall crumbling?

YJ Chua, JR Zalcberg

Journal article  |  2008  |  Annals of Oncology

Progress and challenges in the adjuvant treatment of stage II and III colon cancers

Yu Jo Chua, John R Zalcberg

Journal article  |  2008  |  Expert Review of Anticancer Therapy

Role of palifermin in fluorouracil-based therapy for metastatic colorectal cancer

John R Zalcberg, Lee S Rosen, Ehtesham Abdi, Ian D Davis, John Gutheil, Frederick M Schnell, Alessandra Cesano, Urte Gayko, Mon-Gy Chen, Stephen Clarke

Journal article  |  2008  |  Journal of Clinical Oncology

Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: Lessons from the phase 3 trials

Shreyaskumar Patel, John R Zalcberg

Journal article  |  2008  |  European Journal of Cancer

A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma

Karl D Lewis, William A Robinson, Michael J Millward, Alex Powell, Timothy J Price, Damien B Thomson, Euan T Walpole, Andrew M Haydon, Brian R Creese, Kaye L Roberts, John R Zalcberg, Rene Gonzalez

Journal article  |  2008  |  Investigational New Drugs

The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007

E Van Cutsem, M Dicat, K Haustermans, N Arber, J-F Bosset, D Cunningham, A De Gramont, E Diaz-Rubio, M Ducreux, R Goldberg, R Glynne-Jones, D Haller, Y-K Kang, D Kerr, R Labianca, BD Minsky, M Moore, B Nordlinger, P Rougier, W Scheithauer, et al.

Journal article  |  2008  |  Annals of Oncology

Cetuximab for the treatment of colorectal cancer

Derek J Jonker, Chris J O'Callaghan, Christos S Karapetis, John R Zalcberg, Dongsheng Tu, Heather-Jane Au, Scott R Berry, Marianne Krahn, Timothy Price, R John Simes, Niall C Tebbutt, Guy van Hazel, Rafal Wierzbicki, Christiane Langer, Malcolm J Moore

Journal article  |  2007  |  New England Journal of Medicine

Modification of leucovorin dose within a simplified FOLFOX regimen improves tolerability without compromising efficacy

Stephen Clarke, David Goldstein, Paul Mitchell, Michael Michael, Philip Beale, Michael Friedlander, John Zalcberg, Shane White

Journal article  |  2007  |  Clinical Colorectal Cancer

NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.

George D Demetri, Robert S Benjamin, Charles D Blanke, Jean-Yves Blay, Paolo Casali, Haesun Choi, Christopher L Corless, Maria Debiec-Rychter, Ronald P DeMatteo, David S Ettinger, George A Fisher, Christopher DM Fletcher, Alessandro Gronchi, Peter Hohenberger, Miranda Hughes, Heikki Joensuu, Ian Judson, Axel Le Cesne, Robert G Maki, Michael Morse, et al.

Journal article  |  2007  |  JNCCN Journal of the National Comprehensive Cancer Network

The NCCN Soft Tissue Sarcoma Guidelines include a subsection about treatment recommendations for gastrointestinal stromal tumors (..

Severe hypoglycaemia after long-acting octreotide in a patient with an unrecognized malignant insulinoma

ML Healy, SJ Dawson, RML Murray, J Zalcberg, M Jefford

Journal article  |  2007  |  Internal Medicine Journal

A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer

SJ Dawson, M Michael, J Biagi, KF Foo, M Jefford, SY Ngan, T Leong, A Hui, AD Milner, RJS Thomas, JR Zalcberg

Journal article  |  2007  |  Investigational New Drugs

Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis

Val Gebski, Bryan Burmeister, B Mark Smithers, Kerwyn Foo, John Zalcberg, John Simes

Journal article  |  2007  |  The Lancet Oncology

The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006

C Verslype, E Van Cutsem, M Dicato, S Cascinu, D Cunningham, E Diaz-Rubio, B Glimelius, D Haller, K Haustermans, V Heinemann, P Hoff, PG Johnston, D Kerr, R Labianca, C Louvet, B Minsky, M Moore, B Nordlinger, S Pedrazzoli, A Roth, et al.

Conference Proceedings  |  2007  |  Annals of Oncology

Adjuvant and neoadjuvant therapy for gastric carcinoma: An evidence-based review

RN Sullivan, MPN Findlay, J Zalcberg

Journal article  |  2006  |  American Journal of Cancer

The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study

MJ Millward, C House, D Bowtell, L Webster, IN Olver, M Gore, M Copeman, K Lynch, A Yap, Y Wang, PS Cohen, J Zalcberg

Journal article  |  2006  |  British Journal of Cancer

Relationship of hepatic functional Imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination

Michael Michael, Mick Thompson, Rod J Hicks, Paul L Mitchell, Andrew Ellis, Alvin D Milner, Julia Di Iulio, Andrew M Scott, Volker Gurtler, Janelle M Hoskins, Stephen J Clarke, Niall C Tebbut, Kian Foo, Michael Jefford, John R Zalcberg

Journal article  |  2006  |  Clinical Oncology

The multidisciplinary management of patients with cancer

L Mileshkin, J Zalcberg

Journal article  |  2006  |  Annals of Oncology

Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity

Paul L Mitchell, David Goldstein, Michael Michael, Philip Beale, Michael Friedlander, John Zalcberg, Shane White, Jacquelyn A Thomson, Stephen Clarke

Journal article  |  2006  |  Clinical Colorectal Cancer

Pathological response of gastrointestinal stromal tumour to imatinib treatment correlates with tumour KIT mutational status in individual tumour clones

MB Loughrey, V Beshay, A Dobrovic, J Zalcberg, PM Waring

Journal article  |  2006  |  Histopathology

KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib

MB Loughrey, M Trivett, V Beshay, A Dobrovic, S Kovalenko, W Murray, S Lade, H Turner, GA McArthur, J Zalcberg, PM Waring

Journal article  |  2006  |  Histopathology

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

Maria Debiec-Rychter, Raf Sciot, Axel Le Cesne, Marcus Schlemmer, Peter Hohenberger, Allan T van Oosterom, Jean-Yves Blay, Serge Leyvraz, Michel Stul, Paolo G Casali, John Zalcberg, Jaap Verweij, Martine Van Glabbeke, Anne Hagemeijer, Ian Judson

Journal article  |  2006  |  European Journal of Cancer

Special section on music therapy

C O'Callaghan, JR Zalcberg

Journal article  |  2006  |  Journal of the Society for Integrative Oncology

Recent developments in the systemic therapy of advanced gastroesophageal malignancies

K Khamly, M Jefford, M Michael, J Zalcberg

Journal article  |  2006  |  Expert Opinion on Investigational Drugs

Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs

EK Baker, RW Johnstone, JR Zalcberg, A El-Osta

Journal article  |  2005  |  Oncogene

Medical paternalism and expensive unsubsidised drugs

M Jefford, J Savulescu, J Thomson, P Schofield, L Mileshkin, E Agalianos, J Zalcberg

Journal article  |  2005  |  British Medical Journal

Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance

Y Hirokawa, M Arnold, H Nakajima, J Zalcberg, H Maruta

Journal article  |  2005  |  Cancer Biology & Therapy

Erratum: An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin (Cancer Research (May 15, 2005) 65 (4031-4040))

RW Tothill, A Kowalczyk, D Rischin, A Bousioutas, I Haviv, RK Van Laar, PM Waring, J Zalcberg, R Ward, AV Biankin, RL Sutherland, SM Henshall, K Fong, JR Pollack, D Bowtell, AJ Holloway

Journal article  |  2005  |  Cancer Research

Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial

BH Burmeister, BM Smithers, V Gebski, L Fitzgerald, RJ Simes, P Devitt, S Ackland, DC Gotley, D Joseph, J Millar, J North, ET Walpole, JW Denham

Journal article  |  2005  |  Lancet Oncology

Evidence-based adjuvant treatment of resectable pancreatic adenocarcinoma

S Loi, M Findlay, J Zalcberg

Journal article  |  2005  |  American Journal of Cancer

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg

JR Zalcberg, J Verweij, PG Casali, A Le Cesne, P Reichardt, JY Blay, M Schlemmer, M Van Glabbeke, M Brown, IR Judson

Journal article  |  2005  |  European Journal of Cancer

Beyond 5-fluorouracil: new horizons in systemic therapy for advanced colorectal cancer

K Khamly, M Jefford, M Michael, J Zalcberg

Journal article  |  2005  |  Expert Opinion on Investigational Drugs

The contribution of cytotoxic chemotherapy to the management of cancer

L Mileshkin, D Rischin, HM Prince, J Zalcberg

Journal article  |  2005  |  Clinical Oncology

An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin

RW Tothill, A Kowalczyk, D Rischin, A Bousioutas, I Haviv, RK van Laar, PM Waring, J Zalcberg, R Ward, AV Biankin, RL Sutherland, SM Henshall, K Fong, JR Pollack, DDL Bowtell, AJ Holloway

Journal article  |  2005  |  Cancer Research

Recent advances in the systemic therapy of metastatic colorectal cancer

M Jefford, J Zalcberg

Journal article  |  2005  |  American Journal of Cancer

Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO.

J-Y Blay, S Bonvalot, P Casali, H Choi, M Debiec-Richter, AP Dei Tos, J-F Emile, A Gronchi, PCW Hogendoorn, H Joensuu, A Le Cesne, J McClure, J Maurel, N Nupponen, I Ray-Coquard, P Reichardt, R Sciot, S Stroobants, M van Glabbeke, A van Oosterom, et al.

Conference Proceedings  |  2005  |  Annals of Oncology

BACKGROUND: The management of gastrointestinal stromal tumors (GIST) has evolved very rapidly in the last 4 years. The objectives ..

Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients

D Goldstein, P Mitchell, M Michael, P Beale, M Friedlander, J Zalcberg, S White, S Clarke

Journal article  |  2005  |  British Journal of Cancer

Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial

S Loi, SYK Ngan, RJ Hicks, B Mukesh, P Mitchell, M Michael, J Zalcberg, T Leong, D Lim-Joon, J Mackay, D Rischin

Journal article  |  2005  |  British Journal of Cancer

How should we introduce clinical positron emission tomography in the UK? Oncologists need to have a (clearer) view

M Mac Manus, L Peters, G Duchesne, J Zalcberg, RJS Thomas, D Ball, R Hicks

Journal article  |  2004  |  Clinical Oncology

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

J Verweij, PG Casali, J Zalcberg, A LeCesne, P Reichardt, JY Blay, R Issels, A van Oosterom, PCW Hogendoorn, M Van Glabbeke, R Bertulli, I Judson

Journal article  |  2004  |  The Lancet

A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer

SYK Ngan, M Michael, J Mackay, J McKendrick, T Leong, DL Joon, JR Zalcberg

Journal article  |  2004  |  British Journal of Cancer

Systemic or regional chemotherapy for liver metastases from colorectal cancer: Has the wheel stopped spinning?

JR Zalcberg, NE Kemeny

Journal article  |  2004  |  The Cancer Journal

Rapid screening for depression - validation of the Brief Case-Find for Depression (BCD) in medical oncology and palliative care patients

M Jefford, L Mileshkin, K Richards, J Thomson, JP Matthews, J Zalcberg, R Jennens, SA McLachlan, S Wein, Y Antill, DM Clarke

Journal article  |  2004  |  British Journal of Cancer

A novel combination of cisplatin, irinotecan, and capecitabine in patients with advanced cancer

M Jefford, M Michael, MA Rosenthal, ID Davis, M Green, B McClure, J Smith, B Waite, J Zalcberg

Journal article  |  2004  |  Investigational New Drugs

Adjuvant and neoadjuvant therapy for gastric cancer using epirubicin/cisplatin/5-fluorouracil (ECF) and alternative regimens before and after chemoradiation

T Leong, M Michael, K Foo, A Thompson, DL Joon, L Weih, S Ngan, R Thomas, J Zalcberg

Journal article  |  2003  |  British Journal of Cancer

Palliative chemotherapy: a clinical oxymoron

M Jefford, J Zalcberg

Journal article  |  2003  |  The Lancet

Is improving local control sufficient indication for radiotherapy in the management of rectal cancer? A response

SYK Ngan, D Goldstein, M Solomon, J Zalcberg

Journal article  |  2003  |  ANZ Journal of Surgery

A case report of oxaliplatin extravasation

KF Foo, M Michael, G Toner, J Zalcberg

Journal article  |  2003  |  Annals of Oncology

A phase I dose-escalation study of docetaxel with granulocyte colony-stimulating factor support in patients with solid tumours

PLR Mitchell, R Basser, M Chipman, A Grigg, J Cebon, ID Davis, J Zalcberg, S Ng, F Appia, M Green

Journal article  |  2003  |  Annals of Oncology

Applications of positron emission tomography in the development of molecular targeted cancer therapeutics

B Solomon, GA McArthur, C Cullinane, JR Zalcberg, RJ Hicks

Journal article  |  2003  |  BioDrugs

The treatment of carcinoma of the colon and rectum

M MICHAEL, JR ZALCBERG

Book Chapter  |  2003

Variability in administration of 5-fluorouracil and folinic acid in standard treatment regimens for advanced colorectal cancer

JR Zalcberg, SR Harsley, MJ Dooley

Journal article  |  2002  |  Internal Medicine Journal

Rectal cancer in Victoria in 1994: Patterns of reported management

KC Farmer, C Penfold, JL Millar, J Zalcberg, JA McLeish, RJS Thomas, S Lade, VJ Thursfield, GG Giles

Journal article  |  2002  |  ANZ Journal of Surgery

Efficacy, tolerability and management of raltitrexed (Tomudex (TM)) monotherapy in patients with advanced colorectal cancer: a review of phase II/III trials

D Cunningham, J Zalcberg, J Maroun, R James, S Clarke, TS Maughan, M Vincent, J Schulz, MG Baron, T Facchini

Journal article  |  2002  |  European Journal of Cancer

Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation

A El-Osta, P Kantharidis, JR Zalcberg, AP Wolffe

Journal article  |  2002  |  Molecular and Cellular Biology

Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics

D Rischin, SP Ackland, J Smith, MB Garg, S Clarke, MJ Millward, GC Toner, J Zalcberg

Journal article  |  2002  |  Annals of Oncology

Adjuvant therapy for rectal cancer

KF Foo, M Michael, J Zalcberg

Journal article  |  2002  |  Seminars in Colon [amp ] Rectal Surgery

Training general practitioners in flexible sigmoidoscopy to screen for colorectal cancer

JA Martin, B Crotty, D Barbaro, T Higlett, J Zalcberg

Journal article  |  2001  |  ANZ Journal of Surgery

Randomized trial of coordinated psychosocial interventions based on patient self-assessments versus standard care to improve the psychosocial functioning of patients with cancer

SA McLachlan, A Allenby, J Matthews, A Wirth, D Kissane, M Bishop, J Beresford, J Zalcberg

Journal article  |  2001  |  Journal of Clinical Oncology

Pilot study of oral eniluracil/5-FU in the palliation of hormone-refractory prostate cancer

MA Rosenthal, D Thomas, I Davis, G Toner, N Noordin, J Zalcberg

Journal article  |  2001  |  The Prostate Journal

Chemotherapy for advanced colorectal cancer

MM Kirollos, D Munday, M Michael, J Zalcberg, DI Jeffrey

Journal article  |  2001  |  BMJ

Adjuvant radiotherapy for rectal cancer: A systematic overview of 8507 patients from 22 randomised trials

R Gray, R Hills, R Stowe, M Clarke, R Peto, M Buyse, P Piedbois, B Glimelius, D Kerr, S Kodaira, U Metzger, H Nakazato, J Northover, H Rockette, S Wieand, N Wolmark, S Bendtzen, B Glimelius, I Turesson, B Gray, et al.

Journal article  |  2001  |  The Lancet

Chemotherapy for advanced colorectal cancer.

M Michael, JR Zalcberg

Journal article  |  2000  |  BMJ

The optimal 5-fluorouracil regimen for the adjuvant therapy of colon cancer: Where to from here?

M Michael, JR Zalcberg

Journal article  |  2000  |  Annals of Oncology

Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer

RL Basser, C Underhill, I Davis, MD Green, J Cebon, J Zalcberg, J MacMillan, B Cohen, J Marty, RM Fox, CG Begley

Journal article  |  2000  |  Journal of Clinical Oncology

A phase I trial of docetaxel and gemcitabine in patients with advanced cancer

D Rischin, M Boyer, J Smith, M Millward, M Michael, J Bishop, J Zalcberg, J Davison, E Emmett, B McClure

Journal article  |  2000  |  Annals of Oncology

Open label, multi-centre phase II study of raltitrexed ('Tomudex') in patients with inoperable squamous-cell carcinoma of head and neck

SJ Clarke, J Zalcberg, I Olver, PLR Mitchell, D Rischin, D Dalley, M Green, YE Davidson

Journal article  |  2000  |  Annals of Oncology

Use of (F-18)-fluorodeoxyglucose positron emission tomography in monitoring response of recurrent neurotropic desmoplastic melanoma to radiotherapy

A Hannah, M Feigen, G Quong, T Akhurst, SU Berlangieri, A Zimet, J Zalcberg, WJ McKay, AM Scott

Journal article  |  2000  |  Otolaryngology–Head and Neck Surgery

Regulation of MDR1 gene expression: emerging concepts

P Kantharidis, S El-Osta, M de Silva, G Lee, XF Hu, J Zalcberg

Journal article  |  2000  |  Drug Resistance Updates

MRP1 not MDR1 gene expression is the predominant mechanism of acquired multidrug resistance in two prostate carcinoma cell lines

J Zalcberg, XF Hu, A Slater, J Parisot, S El-Osta, P Kantharidis, ST Chou, JD Parkin

Journal article  |  2000  |  Prostate Cancer and Prostatic Diseases

Gemcitabine and the blood brain barrier

JR Davis, C Fernandes, JR Zalcberg

Journal article  |  1999  |  Australian and New Zealand Journal of Medicine

Positron emission tomography (PET): experience with a large-field-of-view three-dimensional PET scanner

RJ Hicks, DS Binns, ME Fawcett, RE Ware, V Kalff, AF McKenzie, JP Zalcberg, LJ Peters

Journal article  |  1999  |  Medical Journal of Australia

Phase I and subsequent phase II study of filgrastim (r-met-HuG-CSF) and dose intensified cyclophosphamide plus epirubicin in patients with non-Hodgkin's lymphoma and advanced solid tumors

SM Talbot, DA Westerman, AP Grigg, GC Toner, M Wolf, J Bishop, J McKendrick, J Zalcberg, J Levi, RM Fox, MD Green

Journal article  |  1999  |  Annals of Oncology

Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia

XF Hu, A Slater, P Kantharidis, D Rischin, S Juneja, R Rossi, G Lee, JD Parkin, JR Zalcberg

Journal article  |  1999  |  Blood

Overview of docetaxel (Taxotere)/cisplatin combination in non-small cell lung cancer.

T Le Chevalier, J Bérille, JR Zalcberg, MJ Millward, A Monnier, JY Douillard, MJ McKeage, R James, F Soulas, C Loret, N Bougon, JP Bizzari

Journal article  |  1999  |  Seminars in Oncology

Cisplatin-based chemotherapy is effective in non-small cell lung cancer (NSCLC), although it prolongs survival only modestly. Sing..

Absolute quantitation of MDR1 transcripts using heterologous DNA standards - Validation of the competitive RT-PCR (CRT-PCR) approach

A El-Osta, P Kantharidis, J Zalcberg

Journal article  |  1999  |  BioTechniques

Induction of insulin-like growth factor binding protein expression by ICI 182,780 in a tamoxifen-resistant human breast cancer cell line

JP Parisot, KS Leeding, XF Hu, M DeLuise, JR Zalcberg, LA Bach

Journal article  |  1999  |  Breast Cancer Research and Treatment

Repetitive high-dose therapy with ifosfamide, thiotepa and paclitaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: Results of a phase I study

HM Prince, MJ Millward, D Rischin, D Blakey, P Francis, P Gates, P Chapple, M Quinn, S Juneja, M Wolf, EH Januszewicz, JF Seymour, M Brettell, A Strickland, J Zalcberg, G Richardson, J Scarlett, P Briggs, GC Toner

Journal article  |  1999  |  Annals of Oncology

Physical mapping of a tandem duplication on the long arm of chromosome 7 associated with a multidrug resistant phenotype

MG de Silva, P Kantharidis, SW Scherer, K Rayeroux, L Campbell, LC Tsui, JR Zalcberg

Journal article  |  1999  |  Cancer Genetics and Cytogenetics

Colorectal cancer (multiple letters) [1]

JR Zalcberg, D Yip, TD Bolin, AE Cowen, MG Korman, PJ Prichard, JJ Tjandra

Journal article  |  1999  |  Medical Journal of Australia

Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line

XF Hu, A Slater, D Rischin, P Kantharidis, JD Parkin, J Zalcberg

Journal article  |  1999  |  British Journal of Cancer

Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line

JP Parisot, XF Hu, M DeLuise, JR Zalcberg

Journal article  |  1999  |  British Journal of Cancer

Does biomodulation of 5-fluorouracil improve results?

AF Sobrero, R Herrmann, D Rischin, J Zalcberg

Journal article  |  1999  |  European Journal of Cancer

Relationships among liver and kidney volumes, lean body mass and drug clearance

S Nawaratne, JE Brien, E Seeman, R Fabiny, J Zalcberg, W Cosolo, P Angus, DJ Morgan

Journal article  |  1998  |  British Journal of Clinical Pharmacology

Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number

J Zalcberg, D Kerr, L Seymour, M Palmer

Journal article  |  1998  |  European Journal of Cancer

5-fluorouracil: A pharmacological paradigm in the use of cytotoxics

DM Thomas, JR Zalcberg

Journal article  |  1998  |  Clinical and Experimental Pharmacology and Physiology

Hormone replacement therapy and breast cancer

JR Zalcberg, J Siderov

Journal article  |  1998  |  Medical Journal of Australia

Hormone replacement therapy and breast cancer.

JS Lawson

Journal article  |  1998  |  Medical Journal of Australia

Edrecolomab (monoclonal antibody 17-1A).

JC Adkins, CM Spencer

Journal article  |  1998  |  Drugs

Edrecolomab is a mouse-derived monoclonal IgG2a antibody. It recognises the human tumour-associated antigen CO17-1A which is expre..

Update on adjuvant treatment of colorectal cancer.

JM Stewart, JR Zalcberg

Journal article  |  1998  |  Current Opinion in Oncology

Developments in the adjuvant therapy of colorectal cancer have been reported recently. Important questions regarding the most appr..

Second line treatment options in advanced colorectal cancer

JM Stewart, MJ Millward, JR Zalcberg

Journal article  |  1998  |  European Journal of Cancer

Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer

J Zalcberg, M Millward, J Bishop, M McKeage, A Zimet, G Toner, M Friedlander, C Barter, D Rischin, C Loret, R James, N Bougon, J Berille

Journal article  |  1998  |  Journal of Clinical Oncology

In vitro binding of MX2 (KRN8602) and epirubicin to human plasma protein.

WZ Zhang, W Cosolo, J Zalcberg

Journal article  |  1997  |  Pharmacology

This study compares the human plasma protein binding characteristics of MX2 and epirubicin. The binding characteristics were deter..

Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance

P Kantharidis, A ElOsta, M deSilva, DMP Wall, XF Hu, A Slater, G Nadalin, JD Parkin, JR Zalcberg

Journal article  |  1997  |  Clinical Cancer Research

Overview of the tolerability of 'Tomudex' (raltitrexed): collective clinical experience in advanced colorectal cancer.

J Zalcberg

Conference Proceedings  |  1997  |  Anti-Cancer Drugs

The tolerability of raltitrexed ('Tomudex', formerly ZD1694) was examined during phase I, II and III clinical studies involving ar..

Australian multicentre phase II trial of paclitaxel in women with metastatic breast cancer and prior chemotherapy

M Michael, JF Bishop, JA Levi, DR Bell, JR Zalcberg, ML Friedlander, IN Olver, JG Smith, GC Toner

Journal article  |  1997  |  Medical Journal of Australia

Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer

RL Basser, JEJ Rasko, K Clarke, J Cebon, MD Green, AP Grigg, J Zalcberg, B Cohen, J OByrne, DM Menchaca, RM Fox, CG Begley

Journal article  |  1997  |  Blood

Phase I study of paclitaxel and oral etoposide in previously untreated non-small-cell and extensive small-cell lung cancer

MJ Boyer, J Zalcberg, IN Olver, MJ Millward, G Richardson, MJ McKeage

Journal article  |  1997  |  Annals of Oncology

Accuracy of volume measurement using helical CT

S Nawaratne, R Fabiny, JE Brien, J Zalcberg, W Cosolo, A Whan, DJ Morgan

Journal article  |  1997  |  Journal of Computer Assisted Tomography

Sequential extraction of DNA and DNA-binding proteins from low cell numbers

S ElOsta, P Kantharidis, JR Zalcberg

Journal article  |  1997  |  BioTechniques

Expression of mdr1 and mrp in the normal B-cell homologue of B-cell chronic lymphocytic leukaemia

DMP Wall, S ElOsta, D Tzelepis, I Bertoncello, P Kantharidis, ST Chou, JR Zalcberg, JD Parkin

Journal article  |  1997  |  British Journal of Haematology

Clinical issues in euthanasia.

JR Zalcberg, JD Buchanan

Journal article  |  1997  |  Medical Journal of Australia

We consider the euthanasia debate from the perspective of the clinical interface between doctors, patients and their families-a pe..

Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer

MJ Millward, J Zalcberg, JF Bishop, LK Webster, A Zimet, D Rischin, GC Toner, J Laird, W Cosolo, M Urch, R Bruno, C Loret, R James, C Blanc

Journal article  |  1997  |  Journal of Clinical Oncology

Erratum: Final results of a randomised trial comparing 'Tomudex'® (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. (Ann Oncol (1996) 7 (9) (961-965))

D Cunningham, JR Zalcberg, U Rath, I Oliver, E Van Cutsem, C Svensson, JF Seitz, P Harper, D Kerr, G Perez-Manga

Journal article  |  1997  |  Annals of Oncology

Modulation of the function of human MDR1 P-glycoprotein by the antimalarial drug mefloquine

CD Riffkin, R Chung, DM Wall, JR Zalcberg, AF Cowman, M Foley, L Tilley

Journal article  |  1996  |  Biochemical Pharmacology

Final results of a randomised trial comparing 'Tomudex'(R) (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer

D Cunningham, JR Zalcberg, U Rath, I Oliver, E vanCutsem, C Svensson, JF Seitz, P Harper, D Kerr, G PerezManga

Journal article  |  1996  |  Annals of Oncology

Treatment principles in advanced non-small-cell lung cancer.

CL Scott, JR Zalcberg, LB Irving

Journal article  |  1996  |  ANZ Journal of Surgery

Non-small-cell lung cancer (NSCLC) accounts for more than three quarters of all lung tumours and is the leading cause of deaths du..

Liver transplantation in metastatic carcinoid tumour

ML Coperchini, R Jones, P Angus, A Read, G Schmidt, J Zalcberg

Journal article  |  1996  |  Australian and New Zealand Journal of Medicine

Outpatient chemotherapy: there's no place like home--sometimes.

JR Zalcberg, J Siderov, M Petty

Journal article  |  1996  |  Medical Journal of Australia

A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor

I Smith, A Jones, M Spielmann, M Namer, MD Green, J Bonneterre, HE Wander, T Hatschek, N Wilking, J Zalcberg, J Spiers, L Seymour

Journal article  |  1996  |  British Journal of Cancer

Bilateral orchidectomy and flutamide versus orchidectomy alone in newly diagnosed patients with metastatic carcinoma of the prostate--an Australian multicentre trial.

JR Zalcberg, D Raghaven, V Marshall, PJ Thompson

Journal article  |  1996  |  BJU International

OBJECTIVES: To investigate the hypothesis that maximal androgen blockade improves the outcome of patients with metastatic prostate..

The role of chemotherapy in malignant thymoma.

ML Coperchini, JR Zalcberg

Journal article  |  1996  |  Australian and New Zealand Journal of Medicine

Treatment principles in advanced colorectal cancer.

JR Zalcberg, ML Friedlander, BT Collopy, M Barton, B Gray

Journal article  |  1996  |  ANZ Journal of Surgery

BACKGROUND: Colorectal cancer is an important disease in the Australian community. Whilst there has been much discussion about the..

Cyclosporin a and PSC 833 prevent up-regulation of MDR1 expression by anthracyclines in a human multidrug-resistant cell line

XF Hu, A Slater, DM Wall, JD Parkin, P Kantharidis, JR Zalcberg

Journal article  |  1996  |  Clinical Cancer Research

Hormone replacement therapy and breast cancer: what are the facts?

JR Zalcberg, J Siderov

Journal article  |  1996  |  Medical Journal of Australia

Patients' beliefs about cancer management

J Buchanan, R Borland, W Cosolo, R Millership, I Haines, A Zimet, J Zalcberg

Journal article  |  1996  |  Supportive Care in Cancer

The results of a questionnaire answered by 205 medical patients are reported (100 patients with cancer and 105 with other medical ..

ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group.

JR Zalcberg, D Cunningham, E Van Cutsem, E Francois, J Schornagel, A Adenis, M Green, A Iveson, M Azab, I Seymour

Journal article  |  1996  |  Journal of Clinical Oncology

PURPOSE: Tomudex (ZD1694; Zeneca Ltd, Macclesfield, United Kingdom) appears to have a favorable toxicity profile (defined in phase..

'Tomudex' (ZD1694): a novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. 'Tomudex' International Study Group.

D Cunningham, J Zalcberg, I Smith, M Gore, R Pazdur, H Burris, NJ Meropol, G Kennealey, L Seymour

Journal article  |  1996  |  Annals of Oncology

BACKGROUND: Anti-metabolites such as methotrexate (MTX) and 5-fluorouracil (5-FU) have been used clinically for many years. Althou..

Erratum: Treatment principles in advanced colorectal cancer (Australian and New Zealand Journal of Surgery (1996) 66 (202-205))

JR Zalcberg, ML Friedlander, BT Collopy, M Barton, B Gray

Journal article  |  1996  |  Australian and New Zealand Journal of Surgery

'Tomudex' (ZD1694): Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia

D Cunningham, JR Zalcberg, U Rath, I Olver, E Van Cutsem, C Svensson, JF Seitz, P Harper, D Kerr, G Perez-Manga, M Azab, L Seymour, K Lowery

Journal article  |  1996  |  European Journal of Cancer

The role of 5-fluorouracil dose in the adjuvant therapy of colorectal cancer.

JR Zalcberg, J Siderov, J Simes

Journal article  |  1996  |  Annals of Oncology

BACKGROUND: In many centres, the use of 5-fluorouracil (5-FU) combined with levamisole has become standard therapy for the treatme..

Inheritance of chromosome 7 is associated with a drug-resistant phenotype in somatic cell hybrids

M deSilva, P Kantharidis, DM Wall, L Campbell, V Vrazas, G Nadalin, SJ Kaczmarczyk, XF Hu, JD Parkin, JR Zalcberg

Journal article  |  1996  |  British Journal of Cancer

Hypoxemia due to right-to-left shunt in the carcinoid syndrome; beneficial response to octreotide.

D Hart, JR Zalcberg

Journal article  |  1995  |  Annals of Oncology

'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorectal Cancer Study Group.

D Cunningham, JR Zalcberg, U Rath, I Olver, E Van Cutsem, C Svensson, JF Seitz, P Harper, D Kerr, G Perez-Manga

Journal article  |  1995  |  European Journal of Cancer

'Tomudex' (ZD1694), a direct and specific thymidylate synthase (TS) inhibitor entered phase III studies in November 1993. We prese..

The euthanasia controversy. Decision-making in extreme circumstances.

JR Zalcberg, JD Buchanan

Journal article  |  1995  |  Medical Journal of Australia

QUALITY OF PHARMACOKINETIC RESEARCH IN ONCOLOGY

J SIDEROV, JE BRIEN, DJ MORGAN, J ZALCBERG, W COSOLO